Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.29 USD | +6.02% | +26.52% | -67.38% |
Financials (USD)
Sales 2024 * | 428K | Sales 2025 * | 300K | Capitalization | 7.09M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -33M | EV / Sales 2024 * | 16.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 23.6 x |
P/E ratio 2024 * |
-0.49
x | P/E ratio 2025 * |
-0.59
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on TFF Pharmaceuticals, Inc.
1 day | +6.02% | ||
1 week | +26.52% | ||
Current month | -16.12% | ||
1 month | -26.37% | ||
3 months | -64.88% | ||
6 months | -67.25% | ||
Current year | -67.38% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Kirk Coleman
DFI | Director of Finance/CFO | 51 | 18-01-23 |
Zamaneh Mikhak
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 18-11-30 | |
Brandi Roberts
BRD | Director/Board Member | 50 | 22-03-24 |
Thomas King
BRD | Director/Board Member | 69 | Dec. 12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 2.29 | +6.02% | 63,341 |
24-05-17 | 2.16 | 0.00% | 16,762 |
24-05-16 | 2.16 | +7.46% | 154,264 |
24-05-15 | 2.01 | +8.06% | 50,164 |
24-05-14 | 1.86 | +2.76% | 32,786 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.38% | 6.69M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- TFFP Stock